Andrew J. Murphy, EVP Research at REGENERON PHARMACEUTICALS, INC. (REGN), sold 20,117 shares at $542.37 ($11.0M) on 2020-11-17, disclosed to the SEC on 2020-11-18.
Open-market sale of $11.0M REGN by EVP Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $561.39 | 7,108 | $4.0M | 36.1% |
| 2 | $536.68 | 743 | $399K | 3.6% |
| 3 | $536.68 | 743 | $399K | 3.6% |
| 4 | $537.38 | 229 | $123K | 1.1% |
| 5 | $537.38 | 229 | $123K | 1.1% |
| 6 | $538.37 | 591 |
| $318K |
| 2.9% |
| 7 | $538.37 | 591 | $318K | 2.9% |
| 8 | $539.87 | 42 | $23K | 0.2% |
| 9 | $540.49 | 1,442 | $779K | 7.1% |
| 10 | $540.49 | 1,442 | $779K | 7.1% |
| 11 | $541.42 | 812 | $440K | 4.0% |
| 12 | $541.42 | 812 | $440K | 4.0% |
| 13 | $542.37 | 294 | $159K | 1.4% |
| 14 | $542.37 | 294 | $159K | 1.4% |
| 15 | $543.65 | 467 | $254K | 2.3% |
| 16 | $543.65 | 467 | $254K | 2.3% |
| 17 | $544.01 | 68 | $37K | 0.3% |
| 18 | $545.47 | 171 | $93K | 0.8% |
| 19 | $545.47 | 171 | $93K | 0.8% |
| 20 | $546.61 | 524 | $286K | 2.6% |
| 21 | $546.61 | 524 | $286K | 2.6% |
| 22 | $547.12 | 148 | $81K | 0.7% |
| 23 | $547.12 | 148 | $81K | 0.7% |
| 24 | $548.77 | 216 | $119K | 1.1% |
| 25 | $548.77 | 216 | $119K | 1.1% |
| 26 | $549.67 | 283 | $156K | 1.4% |
| 27 | $549.67 | 283 | $156K | 1.4% |
| 28 | $550.71 | 206 | $113K | 1.0% |
| 29 | $550.71 | 206 | $113K | 1.0% |
| 30 | $551.48 | 141 | $78K | 0.7% |
| 31 | $551.48 | 141 | $78K | 0.7% |
| 32 | $552.88 | 73 | $40K | 0.4% |
| 33 | $553.21 | 64 | $35K | 0.3% |
| 34 | $556.45 | 114 | $63K | 0.6% |
| 35 | $556.45 | 114 | $63K | 0.6% |
| Total | $549.25 avg | 20,117 | $11.0M | 100% |
| Filing → |
| REGN | SELL | 2024-03-15 | $11.0M | — | Filing → |
| REGN | SELL | 2023-12-06 | $10.6M | — | Filing → |
| REGN | SELL | 2023-11-15 | $10.3M | — | Filing → |